Focal segmental glomerulosclerosis secondary to subcutaneous interferon β-1a treatment in a patient with multiple sclerosis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Interferon (IFN)-β is a first line treatment for patients with relapsing remitting multiple sclerosis (RRMS) that has been shown to decrease relapse rates, reduce magnetic resonance imaging (MRI) disease burden and possibly delay onset of disability (Arnason, 2005). There are few reports of nephrotic syndrome related to Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) during treatment with IFN-α (Nishimura et al., 2002; Tola et al., 2003; Rettmar et al., 1995). There are fewer reports of nephrotic syndrome induced by IFN-β (Tola et al., 2003; Auty and Saleh, 2005; Kumasaka et al., 2006). We report a 41 year old African American woman with RRMS that developed FSGS after 3 months of treatment with IFN-β-1a 3 times weekly and review the previously published cases.

Original languageEnglish
Pages (from-to)148-151
Number of pages4
JournalMultiple Sclerosis and Related Disorders
Volume1
Issue number3
DOIs
StatePublished - Jul 1 2012

Fingerprint

Focal Segmental Glomerulosclerosis
Interferons
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Nephrotic Syndrome
Lipoid Nephrosis
Therapeutics
African Americans
Magnetic Resonance Imaging
Recurrence

Keywords

  • Adverse effects
  • Focal segmental glomerulosclerosis
  • Glomerulonephritis
  • Interferon beta
  • Kidney failure
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

@article{a6de66bee77c430d8873d7dd299e9008,
title = "Focal segmental glomerulosclerosis secondary to subcutaneous interferon β-1a treatment in a patient with multiple sclerosis",
abstract = "Interferon (IFN)-β is a first line treatment for patients with relapsing remitting multiple sclerosis (RRMS) that has been shown to decrease relapse rates, reduce magnetic resonance imaging (MRI) disease burden and possibly delay onset of disability (Arnason, 2005). There are few reports of nephrotic syndrome related to Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) during treatment with IFN-α (Nishimura et al., 2002; Tola et al., 2003; Rettmar et al., 1995). There are fewer reports of nephrotic syndrome induced by IFN-β (Tola et al., 2003; Auty and Saleh, 2005; Kumasaka et al., 2006). We report a 41 year old African American woman with RRMS that developed FSGS after 3 months of treatment with IFN-β-1a 3 times weekly and review the previously published cases.",
keywords = "Adverse effects, Focal segmental glomerulosclerosis, Glomerulonephritis, Interferon beta, Kidney failure, Multiple sclerosis",
author = "Leticia Tornes and Silvia Delgado and Monica Garcia-Buitrago and Melissa Ortega and Rammohan, {Kottil W}",
year = "2012",
month = "7",
day = "1",
doi = "10.1016/j.msard.2012.02.002",
language = "English",
volume = "1",
pages = "148--151",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Focal segmental glomerulosclerosis secondary to subcutaneous interferon β-1a treatment in a patient with multiple sclerosis

AU - Tornes, Leticia

AU - Delgado, Silvia

AU - Garcia-Buitrago, Monica

AU - Ortega, Melissa

AU - Rammohan, Kottil W

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Interferon (IFN)-β is a first line treatment for patients with relapsing remitting multiple sclerosis (RRMS) that has been shown to decrease relapse rates, reduce magnetic resonance imaging (MRI) disease burden and possibly delay onset of disability (Arnason, 2005). There are few reports of nephrotic syndrome related to Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) during treatment with IFN-α (Nishimura et al., 2002; Tola et al., 2003; Rettmar et al., 1995). There are fewer reports of nephrotic syndrome induced by IFN-β (Tola et al., 2003; Auty and Saleh, 2005; Kumasaka et al., 2006). We report a 41 year old African American woman with RRMS that developed FSGS after 3 months of treatment with IFN-β-1a 3 times weekly and review the previously published cases.

AB - Interferon (IFN)-β is a first line treatment for patients with relapsing remitting multiple sclerosis (RRMS) that has been shown to decrease relapse rates, reduce magnetic resonance imaging (MRI) disease burden and possibly delay onset of disability (Arnason, 2005). There are few reports of nephrotic syndrome related to Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) during treatment with IFN-α (Nishimura et al., 2002; Tola et al., 2003; Rettmar et al., 1995). There are fewer reports of nephrotic syndrome induced by IFN-β (Tola et al., 2003; Auty and Saleh, 2005; Kumasaka et al., 2006). We report a 41 year old African American woman with RRMS that developed FSGS after 3 months of treatment with IFN-β-1a 3 times weekly and review the previously published cases.

KW - Adverse effects

KW - Focal segmental glomerulosclerosis

KW - Glomerulonephritis

KW - Interferon beta

KW - Kidney failure

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84860518321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860518321&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2012.02.002

DO - 10.1016/j.msard.2012.02.002

M3 - Article

AN - SCOPUS:84860518321

VL - 1

SP - 148

EP - 151

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

IS - 3

ER -